Rycardon® has been launched in the Cyprus in the beginning of the current year (January 2011).

This product is a valuable addition to AEGIS’ Cardiovascular and Metabolism (CVM) portfolio. Rycardon^® is used in the treatment of essential hypertension; Rycardon^® is also indicated for the treatment of renal disease in patients with hypertension and type 2 diabetes mellitus.

For further therapeutic information please consult the Summary of  Product Characteristics (SPC).

SPC RYCARDON^®